Trial Profile
PHOspholamban RElated CArdiomyopathy STudy - Intervention (Efficacy Study of Eplerenone in Presymptomaticphospholamban R14del Carriers)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2021
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Cardiomyopathies; Dilated cardiomyopathy
- Focus Therapeutic Use
- Acronyms i-PHORECAST
- 15 Oct 2021 Status changed from active, no longer recruiting to completed.
- 27 Sep 2019 Planned primary completion date changed from 1 Feb 2021 to 1 Mar 2021.
- 07 May 2018 Planned End Date changed from 1 Apr 2020 to 1 Jul 2021.